Isa J. Houwink, M.D., Ph.D.

Open

• A multi-gene Pharmacogenetic panel to prevent adverse drug reactions in daily primary care practice: an open-label, Mayo Clinic multisite (Mankato-Rochester Primary Care Sites), controlled, implementation study taking the results of the PREPARE Study into Minnesota (PREPARE-Mayo) (PREPARE-Mayo) Rochester, Minn., Mankato, Minn.

  The purpose of this study is to determine whether the implementation of pre-emptive PGx[HSR1]  testing of a panel of clinically relevant PGx markers, to guide the dose and drug selection for 39 commonly prescribed drugs, will result in an overall reduction in the number of clinically relevant drug-genotype associated ADRs which are causally related to the initial drug of inclusion (referred to as ‘index drug’).